Idorsia Ltd. (IDRSF)
5.38
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Idorsia Enterprise Value : 2.970B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.970B |
| October 22, 2026 | 2.970B |
| October 21, 2026 | 2.970B |
| October 20, 2026 | 2.970B |
| October 19, 2026 | 2.970B |
| October 16, 2026 | 2.970B |
| October 15, 2026 | 2.970B |
| October 14, 2026 | 2.970B |
| October 13, 2026 | 2.970B |
| October 12, 2026 | 2.970B |
| October 09, 2026 | 2.970B |
| October 08, 2026 | 2.970B |
| October 07, 2026 | 2.970B |
| October 06, 2026 | 2.970B |
| October 05, 2026 | 2.970B |
| October 02, 2026 | 2.970B |
| October 01, 2026 | 2.975B |
| September 30, 2026 | 2.920B |
| September 29, 2026 | 2.920B |
| September 28, 2026 | 2.920B |
| September 25, 2026 | 2.949B |
| September 24, 2026 | 2.949B |
| September 23, 2026 | 3.028B |
| September 22, 2026 | 3.167B |
| September 21, 2026 | 3.167B |
| Date | Value |
|---|---|
| September 18, 2026 | 3.167B |
| September 17, 2026 | 3.167B |
| September 16, 2026 | 3.173B |
| September 15, 2026 | 3.173B |
| September 14, 2026 | 3.173B |
| September 11, 2026 | 3.173B |
| September 10, 2026 | 3.173B |
| September 09, 2026 | 3.204B |
| September 08, 2026 | 3.204B |
| September 04, 2026 | 3.196B |
| September 03, 2026 | 3.196B |
| September 02, 2026 | 3.199B |
| September 01, 2026 | 3.265B |
| August 31, 2026 | 3.265B |
| August 28, 2026 | 3.462B |
| August 27, 2026 | 3.462B |
| August 26, 2026 | 3.462B |
| August 25, 2026 | 3.462B |
| August 24, 2026 | 3.462B |
| August 21, 2026 | 3.462B |
| August 20, 2026 | 3.478B |
| August 19, 2026 | 3.478B |
| August 18, 2026 | 3.478B |
| August 17, 2026 | 3.593B |
| August 14, 2026 | 3.593B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 36.13B |
| AC Immune SA | 132.13M |
| CRISPR Therapeutics AG | 3.193B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -135.44M |
| Revenue (Quarterly) | 66.88M |
| Total Expenses (Quarterly) | 202.32M |
| EPS Diluted (Quarterly) | -0.5293 |
| Gross Profit Margin (Quarterly) | 72.13% |
| Profit Margin (Quarterly) | -202.5% |
| Earnings Yield | -30.69% |
| Normalized Earnings Yield | -24.51 |